Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Combined Chemotherapy Protocols | 38 | 2024 | 2546 | 2.320 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2024 | 832 | 2.220 |
Why?
|
Clinical Trials, Phase II as Topic | 9 | 2014 | 172 | 1.860 |
Why?
|
Research Design | 10 | 2024 | 597 | 1.760 |
Why?
|
Survival Analysis | 15 | 2022 | 1534 | 1.590 |
Why?
|
Antineoplastic Agents | 28 | 2020 | 2410 | 1.350 |
Why?
|
Neoplasms | 24 | 2024 | 3020 | 1.260 |
Why?
|
Head and Neck Neoplasms | 16 | 2022 | 1062 | 1.140 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2022 | 172 | 1.130 |
Why?
|
Humans | 257 | 2024 | 88715 | 1.110 |
Why?
|
Prostatic Neoplasms | 18 | 2023 | 1766 | 1.010 |
Why?
|
Clinical Trials as Topic | 9 | 2024 | 1146 | 0.990 |
Why?
|
Lung Neoplasms | 15 | 2023 | 2344 | 0.980 |
Why?
|
Aged, 80 and over | 65 | 2024 | 6754 | 0.980 |
Why?
|
Male | 160 | 2024 | 42068 | 0.960 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2023 | 1354 | 0.950 |
Why?
|
Aged | 101 | 2024 | 18988 | 0.930 |
Why?
|
Kidney Neoplasms | 11 | 2022 | 634 | 0.920 |
Why?
|
Phenylurea Compounds | 9 | 2014 | 114 | 0.900 |
Why?
|
Middle Aged | 110 | 2024 | 25741 | 0.900 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 154 | 0.880 |
Why?
|
Female | 162 | 2024 | 45827 | 0.880 |
Why?
|
Adult | 110 | 2024 | 26386 | 0.800 |
Why?
|
Multiple Myeloma | 5 | 2024 | 330 | 0.800 |
Why?
|
Antibodies, Monoclonal, Humanized | 14 | 2023 | 965 | 0.790 |
Why?
|
Carcinoma, Renal Cell | 8 | 2022 | 434 | 0.770 |
Why?
|
Carcinoma, Squamous Cell | 11 | 2022 | 1095 | 0.770 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2021 | 1113 | 0.750 |
Why?
|
Protein Kinase Inhibitors | 10 | 2022 | 602 | 0.750 |
Why?
|
Radiosurgery | 5 | 2023 | 280 | 0.740 |
Why?
|
Treatment Outcome | 48 | 2024 | 8170 | 0.710 |
Why?
|
Data Interpretation, Statistical | 3 | 2018 | 299 | 0.690 |
Why?
|
Maximum Tolerated Dose | 9 | 2019 | 272 | 0.680 |
Why?
|
Glucuronosyltransferase | 6 | 2020 | 186 | 0.670 |
Why?
|
Benzimidazoles | 2 | 2017 | 111 | 0.650 |
Why?
|
Ambulances | 1 | 2018 | 15 | 0.640 |
Why?
|
Adenocarcinoma | 12 | 2023 | 1193 | 0.630 |
Why?
|
Dose-Response Relationship, Drug | 15 | 2020 | 1936 | 0.620 |
Why?
|
Quinolines | 2 | 2020 | 91 | 0.580 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2020 | 785 | 0.570 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 4 | 2022 | 121 | 0.570 |
Why?
|
Quinazolines | 7 | 2016 | 221 | 0.570 |
Why?
|
Air Pollution, Indoor | 4 | 2017 | 64 | 0.560 |
Why?
|
Wounds and Injuries | 2 | 2018 | 253 | 0.550 |
Why?
|
Stomach Neoplasms | 6 | 2020 | 280 | 0.550 |
Why?
|
Proportional Hazards Models | 8 | 2024 | 848 | 0.540 |
Why?
|
Endpoint Determination | 2 | 2024 | 61 | 0.530 |
Why?
|
Hospital Mortality | 1 | 2018 | 386 | 0.530 |
Why?
|
Disease-Free Survival | 17 | 2023 | 1212 | 0.530 |
Why?
|
Sirolimus | 5 | 2022 | 170 | 0.510 |
Why?
|
Pyridines | 7 | 2015 | 315 | 0.510 |
Why?
|
Neoplasm Metastasis | 13 | 2020 | 1107 | 0.510 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2023 | 885 | 0.500 |
Why?
|
Toxoplasmosis, Congenital | 6 | 2015 | 49 | 0.500 |
Why?
|
Niacinamide | 8 | 2014 | 115 | 0.500 |
Why?
|
Androgen Antagonists | 7 | 2023 | 154 | 0.490 |
Why?
|
Prospective Studies | 33 | 2023 | 4253 | 0.490 |
Why?
|
Health Services Accessibility | 1 | 2018 | 423 | 0.490 |
Why?
|
Chicago | 17 | 2020 | 1416 | 0.490 |
Why?
|
Camptothecin | 6 | 2014 | 193 | 0.470 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2015 | 155 | 0.470 |
Why?
|
Esophageal Neoplasms | 6 | 2020 | 331 | 0.470 |
Why?
|
Medical Oncology | 3 | 2024 | 379 | 0.470 |
Why?
|
Indoles | 5 | 2015 | 310 | 0.460 |
Why?
|
Allergens | 4 | 1998 | 183 | 0.460 |
Why?
|
Oropharyngeal Neoplasms | 4 | 2022 | 132 | 0.450 |
Why?
|
Hodgkin Disease | 6 | 2023 | 181 | 0.450 |
Why?
|
Sulfonamides | 5 | 2016 | 317 | 0.430 |
Why?
|
Time Factors | 28 | 2020 | 5309 | 0.430 |
Why?
|
Papillomavirus Infections | 4 | 2022 | 261 | 0.420 |
Why?
|
Cooking | 3 | 2017 | 56 | 0.420 |
Why?
|
Aneurysm, Ruptured | 2 | 2003 | 55 | 0.420 |
Why?
|
Pneumonectomy | 2 | 2008 | 205 | 0.420 |
Why?
|
Cetuximab | 4 | 2020 | 117 | 0.410 |
Why?
|
Neoplasm, Residual | 5 | 2024 | 181 | 0.410 |
Why?
|
Antineoplastic Agents, Immunological | 5 | 2020 | 195 | 0.410 |
Why?
|
Paclitaxel | 7 | 2023 | 477 | 0.400 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 5 | 2015 | 84 | 0.400 |
Why?
|
Angiogenesis Inhibitors | 5 | 2016 | 315 | 0.390 |
Why?
|
Chemoradiotherapy | 5 | 2022 | 309 | 0.380 |
Why?
|
Breast Neoplasms | 14 | 2020 | 2986 | 0.380 |
Why?
|
Sample Size | 3 | 2007 | 128 | 0.380 |
Why?
|
Androgens | 5 | 2023 | 175 | 0.380 |
Why?
|
Disease Progression | 11 | 2023 | 1482 | 0.380 |
Why?
|
Dexamethasone | 7 | 2024 | 344 | 0.380 |
Why?
|
Biomarkers, Tumor | 11 | 2023 | 1530 | 0.370 |
Why?
|
Survival Rate | 14 | 2020 | 1874 | 0.370 |
Why?
|
Papillomaviridae | 3 | 2022 | 156 | 0.370 |
Why?
|
Pleural Neoplasms | 3 | 2018 | 197 | 0.370 |
Why?
|
Myelodysplastic Syndromes | 4 | 2016 | 354 | 0.360 |
Why?
|
Radiation Oncology | 2 | 2022 | 121 | 0.360 |
Why?
|
Vascular Endothelial Growth Factor A | 7 | 2023 | 420 | 0.360 |
Why?
|
Carcinoma | 7 | 2015 | 442 | 0.360 |
Why?
|
Antibodies, Monoclonal | 6 | 2024 | 1399 | 0.350 |
Why?
|
Pharmacogenomic Testing | 2 | 2022 | 98 | 0.350 |
Why?
|
Neoplasms, Experimental | 3 | 2019 | 269 | 0.350 |
Why?
|
Statistics, Nonparametric | 6 | 2018 | 306 | 0.340 |
Why?
|
Adolescent | 26 | 2022 | 9190 | 0.340 |
Why?
|
Mesothelioma | 3 | 2018 | 321 | 0.340 |
Why?
|
Prognosis | 22 | 2022 | 3750 | 0.330 |
Why?
|
Benzenesulfonates | 4 | 2012 | 66 | 0.330 |
Why?
|
Injury Severity Score | 2 | 2021 | 133 | 0.330 |
Why?
|
Fluorouracil | 9 | 2020 | 561 | 0.330 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2014 | 277 | 0.330 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2020 | 615 | 0.320 |
Why?
|
Pharmacogenetics | 5 | 2022 | 443 | 0.320 |
Why?
|
Anesthesiology | 2 | 2022 | 160 | 0.320 |
Why?
|
Retrospective Studies | 23 | 2023 | 8932 | 0.320 |
Why?
|
Genotype | 13 | 2022 | 1848 | 0.320 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2019 | 111 | 0.310 |
Why?
|
Pyrimidines | 4 | 2016 | 372 | 0.310 |
Why?
|
Toxoplasma | 3 | 2015 | 116 | 0.310 |
Why?
|
Serum Albumin | 1 | 2008 | 127 | 0.310 |
Why?
|
Pregnancy | 17 | 2017 | 3000 | 0.310 |
Why?
|
Prostate-Specific Antigen | 11 | 2023 | 358 | 0.300 |
Why?
|
Abortion, Habitual | 4 | 2001 | 33 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2014 | 200 | 0.290 |
Why?
|
Combined Modality Therapy | 11 | 2023 | 1707 | 0.290 |
Why?
|
Ethanol | 3 | 2017 | 250 | 0.280 |
Why?
|
Data Collection | 5 | 2009 | 375 | 0.280 |
Why?
|
Colorectal Neoplasms | 1 | 2014 | 980 | 0.280 |
Why?
|
Immunotherapy, Adoptive | 4 | 2023 | 189 | 0.280 |
Why?
|
Quality of Life | 9 | 2024 | 1655 | 0.270 |
Why?
|
Biomarkers | 7 | 2022 | 1751 | 0.270 |
Why?
|
Polymorphism, Genetic | 4 | 2019 | 824 | 0.260 |
Why?
|
Chromosome Aberrations | 4 | 2007 | 390 | 0.260 |
Why?
|
Asthma | 3 | 1998 | 975 | 0.260 |
Why?
|
Young Adult | 12 | 2022 | 6257 | 0.260 |
Why?
|
Bayes Theorem | 1 | 2007 | 368 | 0.260 |
Why?
|
Molecular Targeted Therapy | 3 | 2020 | 285 | 0.260 |
Why?
|
Computer Simulation | 2 | 2022 | 1096 | 0.260 |
Why?
|
ErbB Receptors | 5 | 2020 | 500 | 0.260 |
Why?
|
Oligopeptides | 2 | 2024 | 188 | 0.260 |
Why?
|
Tumor Escape | 2 | 2017 | 51 | 0.250 |
Why?
|
Drug Monitoring | 3 | 2022 | 119 | 0.250 |
Why?
|
Leukemia | 3 | 2006 | 323 | 0.250 |
Why?
|
Interleukin-2 | 3 | 2012 | 251 | 0.250 |
Why?
|
Mastectomy, Radical | 2 | 1999 | 10 | 0.250 |
Why?
|
Double-Blind Method | 15 | 2012 | 1712 | 0.250 |
Why?
|
Oncogene Proteins, Viral | 2 | 2020 | 34 | 0.250 |
Why?
|
Leucovorin | 4 | 2020 | 224 | 0.240 |
Why?
|
Uterine Myomectomy | 1 | 2024 | 10 | 0.240 |
Why?
|
Benzodioxoles | 2 | 2015 | 16 | 0.240 |
Why?
|
Ipilimumab | 2 | 2021 | 61 | 0.240 |
Why?
|
Postoperative Complications | 5 | 2019 | 2271 | 0.240 |
Why?
|
Anilides | 2 | 2015 | 48 | 0.240 |
Why?
|
Perioperative Care | 3 | 2022 | 168 | 0.240 |
Why?
|
Pregnancy Outcome | 7 | 2017 | 253 | 0.240 |
Why?
|
Cytokines | 4 | 2023 | 801 | 0.240 |
Why?
|
Blood Pressure | 4 | 2017 | 894 | 0.230 |
Why?
|
Pregnatrienes | 1 | 2003 | 14 | 0.230 |
Why?
|
Inflammation | 2 | 2022 | 969 | 0.230 |
Why?
|
Standard of Care | 1 | 2024 | 65 | 0.230 |
Why?
|
Early Growth Response Protein 1 | 2 | 2013 | 56 | 0.230 |
Why?
|
Thrombosis | 2 | 2022 | 301 | 0.230 |
Why?
|
Metformin | 2 | 2018 | 123 | 0.230 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2013 | 261 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 6 | 2018 | 858 | 0.220 |
Why?
|
Vasospasm, Intracranial | 1 | 2003 | 36 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2019 | 592 | 0.220 |
Why?
|
Neoplasm Staging | 12 | 2021 | 1988 | 0.220 |
Why?
|
Prostate | 3 | 2022 | 393 | 0.220 |
Why?
|
Haploinsufficiency | 2 | 2013 | 65 | 0.220 |
Why?
|
C-Reactive Protein | 2 | 2022 | 192 | 0.220 |
Why?
|
Mastectomy | 4 | 2015 | 245 | 0.220 |
Why?
|
Follow-Up Studies | 15 | 2023 | 3647 | 0.220 |
Why?
|
Melanoma | 2 | 2021 | 466 | 0.220 |
Why?
|
Aneurysm | 1 | 2003 | 60 | 0.220 |
Why?
|
Chromosome Deletion | 2 | 2013 | 229 | 0.220 |
Why?
|
Neuroprotective Agents | 1 | 2003 | 96 | 0.220 |
Why?
|
Tumor Burden | 5 | 2017 | 308 | 0.210 |
Why?
|
Dioxolanes | 1 | 2002 | 8 | 0.210 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2023 | 56 | 0.210 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2003 | 139 | 0.210 |
Why?
|
Models, Statistical | 4 | 2012 | 575 | 0.210 |
Why?
|
Probability | 2 | 2022 | 353 | 0.210 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2013 | 102 | 0.210 |
Why?
|
Tramadol | 1 | 2022 | 14 | 0.200 |
Why?
|
Papillomavirus E7 Proteins | 2 | 2020 | 31 | 0.200 |
Why?
|
Database Management Systems | 1 | 2002 | 41 | 0.200 |
Why?
|
Glioblastoma | 1 | 2024 | 265 | 0.200 |
Why?
|
Cytosine | 1 | 2002 | 128 | 0.200 |
Why?
|
Cockroaches | 2 | 1998 | 10 | 0.190 |
Why?
|
Prostatectomy | 2 | 2016 | 476 | 0.190 |
Why?
|
Repressor Proteins | 2 | 2020 | 422 | 0.190 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2016 | 387 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 196 | 0.190 |
Why?
|
Immunity | 1 | 2022 | 141 | 0.190 |
Why?
|
Cerebral Angiography | 1 | 2002 | 197 | 0.190 |
Why?
|
Amitriptyline | 1 | 2001 | 11 | 0.190 |
Why?
|
Androstenes | 2 | 2018 | 45 | 0.190 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 201 | 0.190 |
Why?
|
Hypertension | 3 | 2017 | 736 | 0.190 |
Why?
|
Neurosurgical Procedures | 1 | 2003 | 232 | 0.190 |
Why?
|
DNA, Viral | 1 | 2022 | 261 | 0.190 |
Why?
|
Administration, Oral | 11 | 2020 | 681 | 0.190 |
Why?
|
Cisplatin | 5 | 2023 | 617 | 0.190 |
Why?
|
Household Articles | 2 | 2017 | 15 | 0.190 |
Why?
|
Capecitabine | 2 | 2019 | 98 | 0.190 |
Why?
|
Neoplasm Proteins | 3 | 2016 | 540 | 0.190 |
Why?
|
Immunoassay | 2 | 2019 | 91 | 0.190 |
Why?
|
Academic Medical Centers | 3 | 2019 | 384 | 0.190 |
Why?
|
Uterine Neoplasms | 2 | 2024 | 244 | 0.190 |
Why?
|
Neoplasm Grading | 2 | 2023 | 372 | 0.180 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 359 | 0.180 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 397 | 0.180 |
Why?
|
Epothilones | 2 | 2013 | 13 | 0.180 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.180 |
Why?
|
Vaginal Neoplasms | 1 | 2020 | 84 | 0.180 |
Why?
|
Naltrexone | 4 | 2005 | 136 | 0.180 |
Why?
|
Carcinogens | 1 | 2020 | 111 | 0.180 |
Why?
|
Alleles | 6 | 2013 | 1135 | 0.180 |
Why?
|
Leiomyoma | 1 | 2024 | 200 | 0.180 |
Why?
|
Mice | 17 | 2023 | 11718 | 0.180 |
Why?
|
Gait | 1 | 2001 | 81 | 0.180 |
Why?
|
Intracranial Aneurysm | 1 | 2002 | 176 | 0.180 |
Why?
|
Narcotic Antagonists | 4 | 2005 | 157 | 0.180 |
Why?
|
Pyrrolidinones | 1 | 2020 | 16 | 0.180 |
Why?
|
Antidepressive Agents | 1 | 2001 | 110 | 0.180 |
Why?
|
Cell Cycle Proteins | 3 | 2016 | 401 | 0.180 |
Why?
|
Chromosome Fragile Sites | 2 | 2010 | 6 | 0.180 |
Why?
|
Head Injuries, Penetrating | 1 | 2021 | 55 | 0.180 |
Why?
|
Mitoxantrone | 1 | 2020 | 68 | 0.180 |
Why?
|
Anesthesia | 1 | 2022 | 169 | 0.180 |
Why?
|
Fever | 1 | 2020 | 127 | 0.170 |
Why?
|
Blood Coagulation Disorders | 1 | 2021 | 65 | 0.170 |
Why?
|
Estrogens | 1 | 2020 | 201 | 0.170 |
Why?
|
Cytochrome P-450 CYP2C9 | 1 | 2019 | 20 | 0.170 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2023 | 72 | 0.170 |
Why?
|
Celecoxib | 1 | 2019 | 31 | 0.170 |
Why?
|
Drug Administration Schedule | 7 | 2020 | 894 | 0.170 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 100 | 0.170 |
Why?
|
B7-H1 Antigen | 2 | 2023 | 271 | 0.170 |
Why?
|
Infant, Newborn | 15 | 2017 | 2455 | 0.170 |
Why?
|
Robotic Surgical Procedures | 2 | 2016 | 300 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 394 | 0.170 |
Why?
|
Clinical Chemistry Tests | 1 | 2019 | 11 | 0.170 |
Why?
|
Cohort Studies | 10 | 2021 | 2845 | 0.170 |
Why?
|
Ulcer | 1 | 2019 | 37 | 0.170 |
Why?
|
Child, Preschool | 13 | 2016 | 3690 | 0.160 |
Why?
|
Ileal Diseases | 1 | 2019 | 26 | 0.160 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2022 | 185 | 0.160 |
Why?
|
Mutation | 8 | 2023 | 4121 | 0.160 |
Why?
|
Confidence Intervals | 2 | 1996 | 226 | 0.160 |
Why?
|
Geographic Mapping | 1 | 2018 | 12 | 0.160 |
Why?
|
Pyrroles | 3 | 2015 | 187 | 0.160 |
Why?
|
Electroconvulsive Therapy | 1 | 2019 | 25 | 0.160 |
Why?
|
Brain Ischemia | 1 | 2023 | 402 | 0.160 |
Why?
|
Brain Injuries, Traumatic | 1 | 2021 | 98 | 0.160 |
Why?
|
Decision Support Systems, Clinical | 1 | 2019 | 105 | 0.160 |
Why?
|
Rituximab | 1 | 2019 | 119 | 0.160 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2019 | 42 | 0.160 |
Why?
|
Azacitidine | 2 | 2020 | 139 | 0.160 |
Why?
|
Parathyroidectomy | 1 | 2019 | 77 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2015 | 80 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2023 | 419 | 0.160 |
Why?
|
Pancreatic Neoplasms | 3 | 2019 | 666 | 0.160 |
Why?
|
Animals | 30 | 2023 | 27260 | 0.160 |
Why?
|
Ileum | 1 | 2019 | 160 | 0.160 |
Why?
|
Adoptive Transfer | 2 | 2017 | 169 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 393 | 0.160 |
Why?
|
Neuroblastoma | 1 | 2022 | 394 | 0.160 |
Why?
|
Recurrence | 6 | 2023 | 1136 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.160 |
Why?
|
Brain Neoplasms | 1 | 2024 | 780 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2012 | 1174 | 0.150 |
Why?
|
Induction Chemotherapy | 4 | 2022 | 149 | 0.150 |
Why?
|
Analysis of Variance | 4 | 2010 | 901 | 0.150 |
Why?
|
Pain Management | 1 | 2019 | 137 | 0.150 |
Why?
|
Parathyroid Hormone | 1 | 2019 | 216 | 0.150 |
Why?
|
Salvage Therapy | 3 | 2022 | 235 | 0.150 |
Why?
|
Trauma Centers | 1 | 2018 | 133 | 0.150 |
Why?
|
Laparoscopy | 2 | 2016 | 771 | 0.150 |
Why?
|
Nigeria | 4 | 2020 | 155 | 0.150 |
Why?
|
Antigens, Neoplasm | 3 | 2017 | 332 | 0.150 |
Why?
|
Food | 1 | 2018 | 89 | 0.150 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 294 | 0.150 |
Why?
|
Necrosis | 1 | 2018 | 209 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2019 | 394 | 0.150 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 363 | 0.150 |
Why?
|
Endoscopy | 1 | 2020 | 344 | 0.140 |
Why?
|
Ovarian Neoplasms | 3 | 2012 | 762 | 0.140 |
Why?
|
Calcaneus | 2 | 2007 | 34 | 0.140 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 3201 | 0.140 |
Why?
|
Multivariate Analysis | 8 | 2016 | 985 | 0.140 |
Why?
|
Deoxycytidine | 5 | 2015 | 238 | 0.140 |
Why?
|
Logistic Models | 7 | 2016 | 1207 | 0.140 |
Why?
|
Emergency Service, Hospital | 4 | 2003 | 510 | 0.140 |
Why?
|
Hematologic Neoplasms | 2 | 2014 | 339 | 0.140 |
Why?
|
Erythropoiesis | 2 | 2013 | 51 | 0.140 |
Why?
|
Nuclear Proteins | 2 | 2016 | 725 | 0.140 |
Why?
|
Receptor, ErbB-2 | 2 | 2016 | 237 | 0.140 |
Why?
|
Seasons | 1 | 1998 | 236 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 173 | 0.140 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2017 | 108 | 0.140 |
Why?
|
Erlotinib Hydrochloride | 4 | 2011 | 90 | 0.140 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 2016 | 25 | 0.140 |
Why?
|
Hypersensitivity | 1 | 1998 | 158 | 0.140 |
Why?
|
Area Under Curve | 5 | 2019 | 336 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 1264 | 0.140 |
Why?
|
Peptide Termination Factors | 1 | 2016 | 5 | 0.140 |
Why?
|
Heart Diseases | 1 | 2019 | 297 | 0.140 |
Why?
|
Receptor, ErbB-3 | 1 | 2016 | 20 | 0.130 |
Why?
|
Critical Care | 1 | 2019 | 379 | 0.130 |
Why?
|
Unrelated Donors | 1 | 2016 | 44 | 0.130 |
Why?
|
Forms and Records Control | 2 | 2009 | 16 | 0.130 |
Why?
|
Guanine | 3 | 2014 | 207 | 0.130 |
Why?
|
Radiotherapy Dosage | 5 | 2023 | 470 | 0.130 |
Why?
|
Gastrointestinal Transit | 4 | 2005 | 19 | 0.130 |
Why?
|
Weight Loss | 1 | 1997 | 225 | 0.130 |
Why?
|
Dasatinib | 1 | 2015 | 37 | 0.130 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 363 | 0.130 |
Why?
|
Risk Assessment | 8 | 2019 | 2284 | 0.130 |
Why?
|
Feasibility Studies | 4 | 2022 | 776 | 0.130 |
Why?
|
Exanthema | 2 | 2014 | 38 | 0.130 |
Why?
|
Urothelium | 1 | 2016 | 71 | 0.130 |
Why?
|
Retroviridae | 1 | 2016 | 79 | 0.130 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2015 | 31 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
Mutagenesis, Insertional | 1 | 2016 | 112 | 0.130 |
Why?
|
Colon | 1 | 2019 | 509 | 0.130 |
Why?
|
Immunization | 4 | 2013 | 160 | 0.130 |
Why?
|
Patient Education as Topic | 2 | 2000 | 357 | 0.130 |
Why?
|
Forced Expiratory Volume | 3 | 2008 | 124 | 0.130 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2016 | 159 | 0.130 |
Why?
|
Cancer Vaccines | 2 | 2013 | 160 | 0.130 |
Why?
|
Family Health | 1 | 2015 | 162 | 0.130 |
Why?
|
Gene Expression | 4 | 2014 | 1309 | 0.130 |
Why?
|
Wnt Signaling Pathway | 1 | 2016 | 97 | 0.130 |
Why?
|
Collagen Type I | 1 | 2015 | 72 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2016 | 81 | 0.130 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 338 | 0.130 |
Why?
|
Child | 15 | 2016 | 7108 | 0.130 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 100 | 0.120 |
Why?
|
Transplantation, Autologous | 4 | 2022 | 342 | 0.120 |
Why?
|
Salivary Gland Neoplasms | 1 | 2015 | 67 | 0.120 |
Why?
|
Rheumatic Heart Disease | 1 | 1995 | 30 | 0.120 |
Why?
|
Toxoplasmosis | 1 | 2015 | 66 | 0.120 |
Why?
|
Fathers | 1 | 2015 | 70 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 51 | 0.120 |
Why?
|
Cell Line, Tumor | 7 | 2019 | 2546 | 0.120 |
Why?
|
Cluster Analysis | 1 | 2015 | 371 | 0.120 |
Why?
|
Risk Factors | 11 | 2014 | 5442 | 0.120 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 97 | 0.120 |
Why?
|
Hydrocephalus | 1 | 2015 | 104 | 0.120 |
Why?
|
Spleen | 2 | 2013 | 431 | 0.120 |
Why?
|
Immunologic Memory | 2 | 2013 | 161 | 0.120 |
Why?
|
Myocarditis | 1 | 1995 | 52 | 0.120 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 92 | 0.120 |
Why?
|
Urinary Catheters | 1 | 2014 | 6 | 0.120 |
Why?
|
Stroke | 1 | 2023 | 980 | 0.120 |
Why?
|
Angiopoietin-2 | 1 | 2014 | 17 | 0.120 |
Why?
|
Gene Amplification | 1 | 2014 | 134 | 0.120 |
Why?
|
Indazoles | 4 | 2016 | 67 | 0.120 |
Why?
|
Lymph Node Excision | 1 | 2015 | 220 | 0.120 |
Why?
|
Genes, APC | 1 | 2013 | 27 | 0.120 |
Why?
|
Signal Transduction | 6 | 2015 | 3370 | 0.120 |
Why?
|
Urinary Catheterization | 1 | 2014 | 36 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 442 | 0.110 |
Why?
|
Testosterone | 3 | 2018 | 275 | 0.110 |
Why?
|
Antigens, CD34 | 2 | 2008 | 158 | 0.110 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2013 | 41 | 0.110 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2008 | 166 | 0.110 |
Why?
|
Oxidative Stress | 1 | 2016 | 456 | 0.110 |
Why?
|
Mass Spectrometry | 1 | 2014 | 193 | 0.110 |
Why?
|
Genes, p53 | 1 | 2013 | 109 | 0.110 |
Why?
|
Infant | 6 | 2023 | 3128 | 0.110 |
Why?
|
Receptors, Growth Factor | 2 | 2011 | 52 | 0.110 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2013 | 109 | 0.110 |
Why?
|
Bacterial Vaccines | 1 | 2013 | 42 | 0.110 |
Why?
|
Blood Proteins | 1 | 2014 | 145 | 0.110 |
Why?
|
Myeloid Cells | 1 | 2013 | 100 | 0.110 |
Why?
|
Kerosene | 3 | 2017 | 17 | 0.110 |
Why?
|
Receptor, EphB4 | 1 | 2013 | 24 | 0.110 |
Why?
|
Transcription Factors | 4 | 2016 | 1650 | 0.110 |
Why?
|
Food-Drug Interactions | 1 | 2013 | 18 | 0.110 |
Why?
|
Drainage | 1 | 2014 | 158 | 0.110 |
Why?
|
Public Opinion | 1 | 1993 | 42 | 0.110 |
Why?
|
Age Factors | 7 | 2019 | 1861 | 0.110 |
Why?
|
Histones | 3 | 2016 | 329 | 0.110 |
Why?
|
Carboplatin | 3 | 2022 | 304 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 2 | 2009 | 2644 | 0.110 |
Why?
|
Melanoma, Experimental | 1 | 2013 | 104 | 0.110 |
Why?
|
T-Lymphocytes | 5 | 2012 | 1222 | 0.110 |
Why?
|
Peritoneal Neoplasms | 2 | 2012 | 184 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 2 | 2011 | 76 | 0.110 |
Why?
|
Coombs Test | 2 | 2002 | 8 | 0.110 |
Why?
|
Erythroblastosis, Fetal | 2 | 2002 | 11 | 0.110 |
Why?
|
src-Family Kinases | 1 | 2012 | 76 | 0.110 |
Why?
|
Resource Allocation | 1 | 1993 | 65 | 0.110 |
Why?
|
Random Allocation | 4 | 2003 | 328 | 0.110 |
Why?
|
Obesity | 2 | 1997 | 956 | 0.110 |
Why?
|
Remission Induction | 4 | 2020 | 738 | 0.100 |
Why?
|
Health Care Rationing | 1 | 1993 | 83 | 0.100 |
Why?
|
Pain | 3 | 2022 | 400 | 0.100 |
Why?
|
Device Removal | 1 | 2014 | 167 | 0.100 |
Why?
|
Mice, Knockout | 4 | 2020 | 1989 | 0.100 |
Why?
|
Crohn Disease | 1 | 2019 | 754 | 0.100 |
Why?
|
Bevacizumab | 5 | 2012 | 287 | 0.100 |
Why?
|
Proteins | 2 | 2016 | 786 | 0.100 |
Why?
|
Proteomics | 1 | 2014 | 230 | 0.100 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2013 | 169 | 0.100 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.100 |
Why?
|
Translocation, Genetic | 2 | 2019 | 266 | 0.100 |
Why?
|
Carbon Monoxide | 3 | 2017 | 93 | 0.100 |
Why?
|
Peptides | 1 | 2015 | 646 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 275 | 0.100 |
Why?
|
Food Contamination | 1 | 2011 | 32 | 0.100 |
Why?
|
Trastuzumab | 2 | 2023 | 70 | 0.100 |
Why?
|
MAP Kinase Kinase 4 | 2 | 2002 | 67 | 0.100 |
Why?
|
Carcinoma, Large Cell | 1 | 2011 | 39 | 0.100 |
Why?
|
Maintenance Chemotherapy | 2 | 2024 | 84 | 0.100 |
Why?
|
Ear, External | 1 | 1991 | 26 | 0.100 |
Why?
|
Attitude to Health | 1 | 1993 | 221 | 0.100 |
Why?
|
Databases, Factual | 2 | 2016 | 848 | 0.100 |
Why?
|
Thalidomide | 1 | 2011 | 57 | 0.100 |
Why?
|
Genes, Tumor Suppressor | 2 | 2002 | 159 | 0.100 |
Why?
|
Delivery, Obstetric | 3 | 1998 | 118 | 0.100 |
Why?
|
Tissue Banks | 1 | 2011 | 16 | 0.100 |
Why?
|
Insulin | 7 | 1995 | 1145 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 409 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2020 | 1428 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 3440 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 1991 | 64 | 0.090 |
Why?
|
Eating | 1 | 2011 | 165 | 0.090 |
Why?
|
Mouth Neoplasms | 2 | 2007 | 198 | 0.090 |
Why?
|
Thoracic Neoplasms | 1 | 2011 | 64 | 0.090 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 319 | 0.090 |
Why?
|
Lymph Nodes | 4 | 2022 | 548 | 0.090 |
Why?
|
Macrophages | 1 | 2013 | 570 | 0.090 |
Why?
|
Severity of Illness Index | 4 | 2020 | 1834 | 0.090 |
Why?
|
DNA-Binding Proteins | 4 | 2016 | 1241 | 0.090 |
Why?
|
Drug Interactions | 4 | 2019 | 244 | 0.090 |
Why?
|
Breath Tests | 4 | 2002 | 57 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 161 | 0.090 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2010 | 13 | 0.090 |
Why?
|
Risk | 4 | 2007 | 657 | 0.090 |
Why?
|
Coronary Disease | 1 | 1991 | 260 | 0.090 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2010 | 36 | 0.090 |
Why?
|
United States | 9 | 2018 | 6905 | 0.090 |
Why?
|
Schwann Cells | 1 | 2009 | 34 | 0.090 |
Why?
|
Morphine | 2 | 2002 | 130 | 0.090 |
Why?
|
DNA Replication | 2 | 2010 | 169 | 0.090 |
Why?
|
Everolimus | 2 | 2022 | 40 | 0.090 |
Why?
|
Lymphatic Metastasis | 5 | 2015 | 502 | 0.090 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 29 | 0.090 |
Why?
|
Mice, Transgenic | 5 | 2013 | 1573 | 0.090 |
Why?
|
Leukemia, Myeloid | 3 | 2007 | 249 | 0.090 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 103 | 0.080 |
Why?
|
Practice Management, Medical | 1 | 2009 | 23 | 0.080 |
Why?
|
Odds Ratio | 3 | 2015 | 685 | 0.080 |
Why?
|
Risk Management | 1 | 2009 | 42 | 0.080 |
Why?
|
Mastectomy, Extended Radical | 1 | 1989 | 1 | 0.080 |
Why?
|
Radiography, Thoracic | 1 | 1991 | 319 | 0.080 |
Why?
|
Genome-Wide Association Study | 2 | 2014 | 1667 | 0.080 |
Why?
|
Antibodies, Protozoan | 3 | 2015 | 42 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 347 | 0.080 |
Why?
|
Withholding Treatment | 2 | 2024 | 117 | 0.080 |
Why?
|
Patient Selection | 1 | 1993 | 682 | 0.080 |
Why?
|
Glucocorticoids | 2 | 2018 | 356 | 0.080 |
Why?
|
Quality of Health Care | 3 | 2001 | 384 | 0.080 |
Why?
|
Outpatients | 1 | 2009 | 99 | 0.080 |
Why?
|
Prednisone | 3 | 2019 | 258 | 0.080 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2008 | 24 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 60 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2021 | 156 | 0.080 |
Why?
|
Neoplasms, Second Primary | 2 | 2003 | 259 | 0.080 |
Why?
|
Tumor Necrosis Factors | 1 | 2008 | 14 | 0.080 |
Why?
|
Bystander Effect | 1 | 2008 | 12 | 0.080 |
Why?
|
Drug Synergism | 3 | 2018 | 305 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2010 | 277 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 1991 | 350 | 0.080 |
Why?
|
Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
Medical Errors | 1 | 2009 | 116 | 0.080 |
Why?
|
Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
Biopsy | 3 | 2023 | 1180 | 0.080 |
Why?
|
Insurance, Health | 1 | 2009 | 159 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2013 | 447 | 0.080 |
Why?
|
Wood | 2 | 2017 | 19 | 0.080 |
Why?
|
Protein Kinases | 1 | 2009 | 213 | 0.080 |
Why?
|
Cytogenetic Analysis | 3 | 2019 | 71 | 0.070 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2008 | 108 | 0.070 |
Why?
|
Lymphocytes | 5 | 1990 | 471 | 0.070 |
Why?
|
Neutropenia | 2 | 2008 | 216 | 0.070 |
Why?
|
Blood Viscosity | 1 | 2007 | 16 | 0.070 |
Why?
|
Absorptiometry, Photon | 1 | 2007 | 99 | 0.070 |
Why?
|
Apoptosis | 4 | 2013 | 1714 | 0.070 |
Why?
|
Tubulin Modulators | 1 | 2007 | 24 | 0.070 |
Why?
|
Reishi | 1 | 2007 | 7 | 0.070 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 5 | 2002 | 118 | 0.070 |
Why?
|
Acute Disease | 4 | 2022 | 837 | 0.070 |
Why?
|
Peripheral Vascular Diseases | 1 | 2007 | 61 | 0.070 |
Why?
|
Antigens | 1 | 2008 | 229 | 0.070 |
Why?
|
C-Peptide | 5 | 1988 | 179 | 0.070 |
Why?
|
DNA Repair | 4 | 2004 | 361 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2016 | 295 | 0.070 |
Why?
|
Bias | 2 | 1998 | 131 | 0.070 |
Why?
|
Cell Survival | 4 | 2016 | 981 | 0.070 |
Why?
|
Toxoplasmosis, Ocular | 1 | 2006 | 17 | 0.070 |
Why?
|
Drugs, Chinese Herbal | 1 | 2007 | 67 | 0.070 |
Why?
|
Phosphorylcholine | 1 | 2006 | 28 | 0.070 |
Why?
|
Deoxyepinephrine | 1 | 1986 | 1 | 0.070 |
Why?
|
Bone Density | 3 | 2007 | 209 | 0.070 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2006 | 33 | 0.070 |
Why?
|
Mexiletine | 1 | 1986 | 3 | 0.070 |
Why?
|
Phosphorylation | 3 | 2018 | 1128 | 0.070 |
Why?
|
Bryostatins | 1 | 2006 | 15 | 0.070 |
Why?
|
Propylamines | 1 | 1986 | 9 | 0.070 |
Why?
|
Analgesics, Opioid | 2 | 2002 | 440 | 0.070 |
Why?
|
Antiprotozoal Agents | 1 | 2006 | 32 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 376 | 0.070 |
Why?
|
Interferon-gamma | 1 | 2008 | 451 | 0.070 |
Why?
|
Postoperative Care | 2 | 2014 | 228 | 0.070 |
Why?
|
Precancerous Conditions | 1 | 2007 | 200 | 0.070 |
Why?
|
Vision Disorders | 1 | 2006 | 75 | 0.070 |
Why?
|
Muscles | 2 | 2023 | 193 | 0.070 |
Why?
|
Glucosephosphate Dehydrogenase Deficiency | 1 | 2005 | 8 | 0.070 |
Why?
|
Birth Weight | 4 | 2017 | 145 | 0.070 |
Why?
|
Immunohistochemistry | 5 | 2014 | 1795 | 0.070 |
Why?
|
Jaundice, Neonatal | 2 | 2002 | 33 | 0.070 |
Why?
|
Bilirubin | 2 | 2004 | 129 | 0.070 |
Why?
|
Linear Models | 3 | 2015 | 421 | 0.070 |
Why?
|
Norepinephrine | 1 | 1986 | 170 | 0.070 |
Why?
|
Benzamides | 2 | 2022 | 237 | 0.070 |
Why?
|
Cesarean Section | 4 | 2001 | 140 | 0.070 |
Why?
|
Hemolysis | 1 | 2005 | 64 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 666 | 0.060 |
Why?
|
Myocardium | 6 | 1986 | 571 | 0.060 |
Why?
|
Evaluation Studies as Topic | 2 | 1998 | 270 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2006 | 695 | 0.060 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2007 | 209 | 0.060 |
Why?
|
Bone Marrow | 3 | 2013 | 445 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 374 | 0.060 |
Why?
|
Fractures, Bone | 1 | 2006 | 126 | 0.060 |
Why?
|
Epithelial Cells | 3 | 2022 | 688 | 0.060 |
Why?
|
Immunotherapy | 2 | 2022 | 663 | 0.060 |
Why?
|
Methyltransferases | 4 | 1990 | 192 | 0.060 |
Why?
|
Thyrotoxicosis | 1 | 2004 | 18 | 0.060 |
Why?
|
Placebos | 3 | 2012 | 214 | 0.060 |
Why?
|
Breech Presentation | 2 | 1994 | 12 | 0.060 |
Why?
|
Cytarabine | 2 | 2020 | 219 | 0.060 |
Why?
|
Genome, Human | 1 | 2009 | 767 | 0.060 |
Why?
|
Carrier Proteins | 2 | 1985 | 679 | 0.060 |
Why?
|
Plant Preparations | 1 | 2004 | 20 | 0.060 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2008 | 50 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 468 | 0.060 |
Why?
|
Quinolones | 1 | 2004 | 60 | 0.060 |
Why?
|
Pain, Postoperative | 2 | 2019 | 251 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 1 | 1986 | 197 | 0.060 |
Why?
|
Barrett Esophagus | 1 | 2005 | 93 | 0.060 |
Why?
|
Glutathione | 1 | 2004 | 108 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2006 | 235 | 0.060 |
Why?
|
Dopamine | 1 | 1986 | 276 | 0.060 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2004 | 34 | 0.060 |
Why?
|
Lymphoma, T-Cell | 1 | 2004 | 55 | 0.060 |
Why?
|
Suramin | 1 | 2004 | 27 | 0.060 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2004 | 58 | 0.060 |
Why?
|
Receptors, Estrogen | 2 | 1987 | 386 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2007 | 490 | 0.060 |
Why?
|
Nimodipine | 1 | 2003 | 11 | 0.060 |
Why?
|
RNA, Small Interfering | 3 | 2013 | 557 | 0.060 |
Why?
|
Abortion, Spontaneous | 1 | 2004 | 66 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2003 | 27 | 0.060 |
Why?
|
Warfarin | 1 | 2004 | 104 | 0.060 |
Why?
|
Thyroid Hormone Resistance Syndrome | 1 | 2004 | 117 | 0.060 |
Why?
|
Genomics | 2 | 2023 | 751 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 1985 | 289 | 0.060 |
Why?
|
Urban Population | 3 | 2003 | 223 | 0.060 |
Why?
|
Thyrotropin | 1 | 2004 | 286 | 0.060 |
Why?
|
Circadian Rhythm | 2 | 2009 | 304 | 0.060 |
Why?
|
ras Proteins | 1 | 2004 | 130 | 0.060 |
Why?
|
Health Status | 2 | 1999 | 370 | 0.060 |
Why?
|
Injections, Intravenous | 6 | 2005 | 240 | 0.060 |
Why?
|
Tissue Array Analysis | 2 | 2016 | 127 | 0.060 |
Why?
|
Phytotherapy | 1 | 2004 | 135 | 0.050 |
Why?
|
Hydroxyurea | 2 | 2014 | 239 | 0.050 |
Why?
|
Angiography | 1 | 2003 | 208 | 0.050 |
Why?
|
Iodine Radioisotopes | 1 | 2023 | 134 | 0.050 |
Why?
|
Colonic Pouches | 1 | 2003 | 68 | 0.050 |
Why?
|
Mass Screening | 1 | 2007 | 629 | 0.050 |
Why?
|
Imides | 1 | 2022 | 26 | 0.050 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2022 | 29 | 0.050 |
Why?
|
Rh Isoimmunization | 1 | 2002 | 7 | 0.050 |
Why?
|
Asparaginase | 1 | 2022 | 35 | 0.050 |
Why?
|
Panax | 1 | 2004 | 170 | 0.050 |
Why?
|
Proctocolectomy, Restorative | 1 | 2003 | 88 | 0.050 |
Why?
|
Proteasome Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
|
Mice, Inbred C3H | 2 | 2013 | 371 | 0.050 |
Why?
|
Androgen Receptor Antagonists | 1 | 2022 | 22 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2018 | 205 | 0.050 |
Why?
|
Hydralazine | 1 | 2022 | 19 | 0.050 |
Why?
|
Mifepristone | 1 | 2022 | 33 | 0.050 |
Why?
|
Pelvis | 1 | 2022 | 95 | 0.050 |
Why?
|
Intracranial Hemorrhages | 1 | 2023 | 128 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 2 | 1995 | 265 | 0.050 |
Why?
|
Peripheral Nervous System | 1 | 2002 | 21 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2004 | 328 | 0.050 |
Why?
|
Quaternary Ammonium Compounds | 4 | 2005 | 80 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2012 | 690 | 0.050 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 48 | 0.050 |
Why?
|
Radiotherapy, High-Energy | 2 | 2010 | 49 | 0.050 |
Why?
|
Oxycodone | 1 | 2022 | 35 | 0.050 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2022 | 52 | 0.050 |
Why?
|
Thrombectomy | 1 | 2023 | 173 | 0.050 |
Why?
|
Patient Satisfaction | 2 | 2003 | 461 | 0.050 |
Why?
|
Gene Dosage | 2 | 2013 | 208 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 1999 | 207 | 0.050 |
Why?
|
Nitriles | 1 | 2022 | 160 | 0.050 |
Why?
|
Office Management | 1 | 1981 | 1 | 0.050 |
Why?
|
Patient Reported Outcome Measures | 1 | 2023 | 190 | 0.050 |
Why?
|
Filing | 1 | 1981 | 3 | 0.050 |
Why?
|
Vaginal Birth after Cesarean | 1 | 2001 | 7 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 780 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2004 | 345 | 0.050 |
Why?
|
Smoking | 2 | 2016 | 620 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 267 | 0.050 |
Why?
|
Geriatric Assessment | 1 | 2003 | 182 | 0.050 |
Why?
|
Desipramine | 1 | 2001 | 9 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2019 | 2347 | 0.050 |
Why?
|
Computers | 1 | 1981 | 112 | 0.050 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.050 |
Why?
|
Triazolam | 1 | 2000 | 5 | 0.050 |
Why?
|
Health Services for the Aged | 1 | 2001 | 32 | 0.050 |
Why?
|
Paroxetine | 1 | 2001 | 26 | 0.050 |
Why?
|
Anticoagulants | 1 | 2004 | 425 | 0.050 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2000 | 13 | 0.050 |
Why?
|
Receptors, Glucocorticoid | 1 | 2022 | 131 | 0.050 |
Why?
|
Anti-Anxiety Agents | 1 | 2000 | 23 | 0.050 |
Why?
|
Hepatocyte Growth Factor | 2 | 2011 | 85 | 0.050 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 114 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2020 | 38 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2001 | 200 | 0.050 |
Why?
|
Vincristine | 2 | 2019 | 112 | 0.050 |
Why?
|
Hemorrhage | 1 | 2022 | 277 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 887 | 0.050 |
Why?
|
HLA Antigens | 1 | 2001 | 227 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2020 | 56 | 0.040 |
Why?
|
Ethylnitrosourea | 2 | 2013 | 30 | 0.040 |
Why?
|
Drug Utilization Review | 1 | 1999 | 14 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 155 | 0.040 |
Why?
|
Mucositis | 2 | 2010 | 18 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 1999 | 27 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2003 | 217 | 0.040 |
Why?
|
Mortality | 1 | 2001 | 149 | 0.040 |
Why?
|
Prevalence | 2 | 2015 | 1237 | 0.040 |
Why?
|
Needs Assessment | 1 | 2001 | 158 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 136 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 1999 | 22 | 0.040 |
Why?
|
Dogs | 3 | 1998 | 704 | 0.040 |
Why?
|
Medication Errors | 1 | 1999 | 39 | 0.040 |
Why?
|
Methadone | 1 | 2000 | 45 | 0.040 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 164 | 0.040 |
Why?
|
Doxorubicin | 2 | 2019 | 298 | 0.040 |
Why?
|
Hydrazines | 1 | 2019 | 31 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2018 | 188 | 0.040 |
Why?
|
Tumor Cells, Cultured | 4 | 2004 | 1057 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 1999 | 53 | 0.040 |
Why?
|
Constipation | 1 | 2000 | 63 | 0.040 |
Why?
|
Gestational Age | 2 | 2017 | 323 | 0.040 |
Why?
|
Catheterization, Peripheral | 1 | 1999 | 60 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2023 | 481 | 0.040 |
Why?
|
Retreatment | 1 | 2019 | 108 | 0.040 |
Why?
|
Albumins | 1 | 2019 | 129 | 0.040 |
Why?
|
Leukapheresis | 1 | 1999 | 19 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2019 | 90 | 0.040 |
Why?
|
Pilot Projects | 2 | 2018 | 865 | 0.040 |
Why?
|
Emergencies | 1 | 1999 | 120 | 0.040 |
Why?
|
Inflammatory Bowel Diseases | 2 | 1998 | 570 | 0.040 |
Why?
|
Radiography | 2 | 2014 | 808 | 0.040 |
Why?
|
Birth Rate | 1 | 1998 | 12 | 0.040 |
Why?
|
Community Health Services | 1 | 2000 | 82 | 0.040 |
Why?
|
Diarrhea | 2 | 2011 | 182 | 0.040 |
Why?
|
Abiraterone Acetate | 1 | 2018 | 12 | 0.040 |
Why?
|
Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
Postpartum Period | 1 | 2000 | 144 | 0.040 |
Why?
|
Carcinogenesis | 1 | 2020 | 210 | 0.040 |
Why?
|
Hysterectomy | 1 | 2000 | 150 | 0.040 |
Why?
|
Triazoles | 1 | 2019 | 102 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 112 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2007 | 2750 | 0.040 |
Why?
|
Fatigue | 2 | 2011 | 178 | 0.040 |
Why?
|
Etoposide | 1 | 2019 | 198 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 144 | 0.040 |
Why?
|
Singapore | 1 | 2018 | 16 | 0.040 |
Why?
|
Skin Tests | 1 | 1998 | 44 | 0.040 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 46 | 0.040 |
Why?
|
Mites | 1 | 1998 | 16 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 1998 | 147 | 0.040 |
Why?
|
Antigens, Differentiation | 1 | 1998 | 141 | 0.040 |
Why?
|
Cross Infection | 1 | 1999 | 146 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2018 | 49 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2019 | 299 | 0.040 |
Why?
|
Affect | 1 | 2001 | 387 | 0.040 |
Why?
|
Epigenesis, Genetic | 2 | 2014 | 504 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2000 | 314 | 0.040 |
Why?
|
Monocytes | 1 | 1999 | 216 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 343 | 0.040 |
Why?
|
Immunoglobulin M | 2 | 2015 | 163 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2010 | 106 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1999 | 158 | 0.040 |
Why?
|
Incidence | 3 | 2015 | 1588 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.040 |
Why?
|
Body Constitution | 1 | 1997 | 26 | 0.040 |
Why?
|
Cats | 1 | 1998 | 305 | 0.040 |
Why?
|
Piperazines | 2 | 2011 | 283 | 0.040 |
Why?
|
Immunoconjugates | 1 | 1998 | 110 | 0.040 |
Why?
|
Islets of Langerhans | 3 | 1994 | 548 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 336 | 0.040 |
Why?
|
Contrast Media | 2 | 2016 | 1090 | 0.040 |
Why?
|
Nephrotic Syndrome | 1 | 1997 | 33 | 0.040 |
Why?
|
Alcoholism | 1 | 1999 | 178 | 0.040 |
Why?
|
Analgesics, Non-Narcotic | 1 | 1998 | 47 | 0.040 |
Why?
|
Acetaminophen | 1 | 1998 | 55 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2019 | 273 | 0.040 |
Why?
|
Fasting | 1 | 2018 | 163 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2014 | 1711 | 0.040 |
Why?
|
Infant Mortality | 2 | 1994 | 59 | 0.040 |
Why?
|
Psychomotor Performance | 1 | 2001 | 496 | 0.040 |
Why?
|
Leukocytes | 1 | 1998 | 203 | 0.040 |
Why?
|
Digestive System Surgical Procedures | 1 | 2019 | 126 | 0.040 |
Why?
|
Environmental Monitoring | 1 | 2017 | 74 | 0.040 |
Why?
|
Ultrasonography, Prenatal | 1 | 1998 | 152 | 0.040 |
Why?
|
Penicillamine | 1 | 1997 | 12 | 0.040 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 1997 | 21 | 0.040 |
Why?
|
Cell Line | 5 | 2009 | 2494 | 0.040 |
Why?
|
Comorbidity | 1 | 2021 | 946 | 0.040 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 1997 | 29 | 0.040 |
Why?
|
Religion | 1 | 1997 | 88 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 1974 | 0.040 |
Why?
|
Patient Readmission | 1 | 2001 | 351 | 0.040 |
Why?
|
Dust | 1 | 1997 | 26 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 215 | 0.040 |
Why?
|
Household Products | 1 | 2016 | 9 | 0.040 |
Why?
|
Biofuels | 1 | 2016 | 10 | 0.040 |
Why?
|
Cystoscopy | 1 | 1997 | 39 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2017 | 98 | 0.040 |
Why?
|
Colonoscopy | 1 | 2019 | 279 | 0.040 |
Why?
|
Lidocaine | 1 | 1997 | 64 | 0.040 |
Why?
|
Body Mass Index | 2 | 1997 | 763 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 1997 | 55 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 1 | 1999 | 299 | 0.030 |
Why?
|
Social Support | 1 | 1998 | 206 | 0.030 |
Why?
|
Particulate Matter | 1 | 2017 | 102 | 0.030 |
Why?
|
Schools | 1 | 1997 | 73 | 0.030 |
Why?
|
Pregnant Women | 1 | 2016 | 41 | 0.030 |
Why?
|
Unsupervised Machine Learning | 1 | 2016 | 6 | 0.030 |
Why?
|
Colitis, Ulcerative | 1 | 2003 | 733 | 0.030 |
Why?
|
Heart Failure | 1 | 1986 | 1173 | 0.030 |
Why?
|
Cell Differentiation | 3 | 2009 | 1521 | 0.030 |
Why?
|
Air Pollutants | 1 | 2017 | 92 | 0.030 |
Why?
|
Creatinine | 1 | 1997 | 293 | 0.030 |
Why?
|
Waiting Lists | 1 | 1997 | 183 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 1997 | 76 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2015 | 463 | 0.030 |
Why?
|
Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2017 | 164 | 0.030 |
Why?
|
Transcriptome | 1 | 2021 | 626 | 0.030 |
Why?
|
Loss of Heterozygosity | 2 | 2010 | 86 | 0.030 |
Why?
|
Body Weight | 1 | 1997 | 452 | 0.030 |
Why?
|
Cell Cycle | 2 | 2016 | 508 | 0.030 |
Why?
|
DNA Methylation | 2 | 2016 | 657 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2016 | 136 | 0.030 |
Why?
|
Premature Birth | 1 | 2017 | 116 | 0.030 |
Why?
|
Hospital Costs | 1 | 1997 | 107 | 0.030 |
Why?
|
Diabetes Mellitus | 2 | 2000 | 738 | 0.030 |
Why?
|
Margins of Excision | 1 | 2016 | 39 | 0.030 |
Why?
|
Agglutination Tests | 1 | 2015 | 11 | 0.030 |
Why?
|
Serogroup | 1 | 2015 | 9 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
Blotting, Western | 2 | 2010 | 794 | 0.030 |
Why?
|
Prostatic Hyperplasia | 1 | 1997 | 91 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 2008 | 433 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2016 | 231 | 0.030 |
Why?
|
Snake Venoms | 1 | 2015 | 10 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1062 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2018 | 597 | 0.030 |
Why?
|
Heart | 4 | 1986 | 573 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2016 | 260 | 0.030 |
Why?
|
Air Pollution | 1 | 2016 | 92 | 0.030 |
Why?
|
Pain Measurement | 1 | 1997 | 329 | 0.030 |
Why?
|
Likelihood Functions | 1 | 1996 | 251 | 0.030 |
Why?
|
Exercise | 2 | 2014 | 322 | 0.030 |
Why?
|
Visual Acuity | 2 | 2006 | 197 | 0.030 |
Why?
|
Mastectomy, Segmental | 2 | 2010 | 94 | 0.030 |
Why?
|
Reference Values | 5 | 1998 | 661 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2008 | 1011 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2016 | 446 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
Blood Glucose | 6 | 2000 | 835 | 0.030 |
Why?
|
Anemia, Sickle Cell | 1 | 1997 | 144 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 1994 | 57 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2013 | 2879 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 642 | 0.030 |
Why?
|
Skin Window Technique | 1 | 2013 | 3 | 0.030 |
Why?
|
Anemia, Macrocytic | 1 | 2013 | 5 | 0.030 |
Why?
|
Hospitals | 1 | 1997 | 298 | 0.030 |
Why?
|
Receptors, Chemokine | 1 | 2013 | 31 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 2019 | 598 | 0.030 |
Why?
|
CD11b Antigen | 1 | 2013 | 36 | 0.030 |
Why?
|
Taxoids | 1 | 2014 | 130 | 0.030 |
Why?
|
Genes, Lethal | 1 | 2013 | 53 | 0.030 |
Why?
|
Erythroblasts | 1 | 2013 | 25 | 0.030 |
Why?
|
Pemetrexed | 1 | 2014 | 76 | 0.030 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 1986 | 115 | 0.030 |
Why?
|
Cellular Microenvironment | 1 | 2013 | 29 | 0.030 |
Why?
|
Glutamates | 1 | 2014 | 89 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 22 | 0.030 |
Why?
|
Pyrimethamine | 2 | 2006 | 21 | 0.030 |
Why?
|
Aspirin | 1 | 1995 | 159 | 0.030 |
Why?
|
Quality Control | 2 | 1986 | 117 | 0.030 |
Why?
|
Sulfadiazine | 2 | 2006 | 24 | 0.030 |
Why?
|
S Phase | 2 | 2010 | 63 | 0.030 |
Why?
|
Genes, ras | 1 | 2013 | 98 | 0.030 |
Why?
|
Muscular Dystrophies | 2 | 1984 | 55 | 0.030 |
Why?
|
Ovalbumin | 1 | 2013 | 109 | 0.030 |
Why?
|
Erythropoietin | 1 | 2013 | 88 | 0.030 |
Why?
|
Autopsy | 1 | 2013 | 122 | 0.030 |
Why?
|
Polycystic Ovary Syndrome | 1 | 1995 | 206 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2013 | 131 | 0.030 |
Why?
|
Insulin Resistance | 1 | 1995 | 353 | 0.030 |
Why?
|
Epitopes | 1 | 2013 | 255 | 0.030 |
Why?
|
Cystic Fibrosis | 1 | 1994 | 116 | 0.030 |
Why?
|
Treatment Refusal | 1 | 1993 | 62 | 0.030 |
Why?
|
Imidazoles | 1 | 2013 | 148 | 0.030 |
Why?
|
Life Support Care | 1 | 1993 | 50 | 0.030 |
Why?
|
Moral Obligations | 1 | 1993 | 53 | 0.030 |
Why?
|
Heterozygote | 1 | 2013 | 373 | 0.030 |
Why?
|
Gene Deletion | 1 | 2013 | 342 | 0.030 |
Why?
|
Serotyping | 1 | 2012 | 28 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 129 | 0.030 |
Why?
|
Cell Membrane | 5 | 1986 | 668 | 0.030 |
Why?
|
Kidney | 1 | 1997 | 1145 | 0.030 |
Why?
|
Intraocular Pressure | 1 | 1992 | 57 | 0.030 |
Why?
|
Infant, Premature | 1 | 1994 | 295 | 0.030 |
Why?
|
Autoantibodies | 1 | 1993 | 268 | 0.030 |
Why?
|
United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2013 | 215 | 0.030 |
Why?
|
Up-Regulation | 1 | 2014 | 727 | 0.030 |
Why?
|
Oocysts | 1 | 2011 | 7 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.030 |
Why?
|
Glucose | 3 | 1995 | 628 | 0.030 |
Why?
|
Hospitalization | 1 | 1997 | 871 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 470 | 0.020 |
Why?
|
Orchiectomy | 1 | 2011 | 72 | 0.020 |
Why?
|
Death, Sudden | 1 | 1991 | 40 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2013 | 461 | 0.020 |
Why?
|
North America | 1 | 2011 | 184 | 0.020 |
Why?
|
Virulence | 1 | 2012 | 277 | 0.020 |
Why?
|
Pleural Effusion | 1 | 1991 | 47 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 268 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 85 | 0.020 |
Why?
|
MAP Kinase Signaling System | 2 | 2002 | 197 | 0.020 |
Why?
|
Regression Analysis | 2 | 2009 | 589 | 0.020 |
Why?
|
Phospholipids | 2 | 2006 | 111 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2013 | 319 | 0.020 |
Why?
|
Pneumothorax | 1 | 1991 | 53 | 0.020 |
Why?
|
Herbicides | 1 | 1990 | 36 | 0.020 |
Why?
|
Uterine Diseases | 2 | 2001 | 19 | 0.020 |
Why?
|
Uterine Hemorrhage | 2 | 2001 | 20 | 0.020 |
Why?
|
Universities | 1 | 2011 | 146 | 0.020 |
Why?
|
Tissue Donors | 1 | 1994 | 489 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 389 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2011 | 354 | 0.020 |
Why?
|
Enzyme Activation | 2 | 2002 | 698 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2013 | 751 | 0.020 |
Why?
|
Models, Biological | 3 | 2013 | 1763 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2010 | 37 | 0.020 |
Why?
|
Aphidicolin | 1 | 2010 | 4 | 0.020 |
Why?
|
Replication Origin | 1 | 2010 | 5 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 230 | 0.020 |
Why?
|
Hospitals, University | 2 | 2001 | 195 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2010 | 73 | 0.020 |
Why?
|
Veterans | 1 | 1990 | 83 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2013 | 554 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 921 | 0.020 |
Why?
|
Intubation, Intratracheal | 1 | 1991 | 147 | 0.020 |
Why?
|
Blood Transfusion | 2 | 2001 | 165 | 0.020 |
Why?
|
Cell Movement | 1 | 2013 | 783 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 606 | 0.020 |
Why?
|
Sister Chromatid Exchange | 1 | 1989 | 13 | 0.020 |
Why?
|
Acetylation | 1 | 2009 | 132 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2010 | 283 | 0.020 |
Why?
|
Castration | 1 | 2009 | 41 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 157 | 0.020 |
Why?
|
Tamoxifen | 1 | 2010 | 168 | 0.020 |
Why?
|
Genomic Instability | 1 | 2009 | 79 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2009 | 60 | 0.020 |
Why?
|
Muscle Strength | 1 | 2009 | 30 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2006 | 2011 | 0.020 |
Why?
|
Brachytherapy | 1 | 2010 | 121 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 1 | 2009 | 50 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 543 | 0.020 |
Why?
|
Demography | 1 | 2009 | 181 | 0.020 |
Why?
|
Pneumonia | 1 | 2010 | 182 | 0.020 |
Why?
|
Morbidity | 2 | 1999 | 148 | 0.020 |
Why?
|
Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
Receptors, Interferon | 1 | 2008 | 31 | 0.020 |
Why?
|
Filgrastim | 1 | 2008 | 57 | 0.020 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2008 | 20 | 0.020 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2008 | 42 | 0.020 |
Why?
|
Radiotherapy | 1 | 2010 | 331 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2008 | 90 | 0.020 |
Why?
|
Tolonium Chloride | 1 | 2007 | 5 | 0.020 |
Why?
|
Imatinib Mesylate | 1 | 2008 | 127 | 0.020 |
Why?
|
Mercaptoethylamines | 1 | 1988 | 52 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2008 | 79 | 0.020 |
Why?
|
Spectrophotometry | 1 | 2007 | 108 | 0.020 |
Why?
|
Cytological Techniques | 1 | 2007 | 30 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2009 | 260 | 0.020 |
Why?
|
Coloring Agents | 1 | 2007 | 65 | 0.020 |
Why?
|
Intensive Care Units | 1 | 1991 | 392 | 0.020 |
Why?
|
Fluorescence | 1 | 2007 | 103 | 0.020 |
Why?
|
Rheology | 1 | 2007 | 39 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2008 | 142 | 0.020 |
Why?
|
Radiation-Protective Agents | 1 | 1988 | 98 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2008 | 264 | 0.020 |
Why?
|
Microscopy, Electron | 5 | 1986 | 510 | 0.020 |
Why?
|
CD56 Antigen | 1 | 2007 | 18 | 0.020 |
Why?
|
Thirst | 1 | 2007 | 19 | 0.020 |
Why?
|
Stromal Cells | 1 | 2008 | 151 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 1649 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2009 | 311 | 0.020 |
Why?
|
Phenotype | 1 | 2013 | 2438 | 0.020 |
Why?
|
Length of Stay | 2 | 2003 | 728 | 0.020 |
Why?
|
Mammography | 1 | 2010 | 469 | 0.020 |
Why?
|
Wechsler Scales | 1 | 2006 | 21 | 0.020 |
Why?
|
Vision, Monocular | 1 | 2006 | 15 | 0.020 |
Why?
|
Intelligence Tests | 1 | 2006 | 38 | 0.020 |
Why?
|
Femur Neck | 1 | 2006 | 41 | 0.020 |
Why?
|
Chromatin | 1 | 2009 | 397 | 0.020 |
Why?
|
Language Tests | 1 | 2006 | 37 | 0.020 |
Why?
|
Macula Lutea | 1 | 2006 | 19 | 0.020 |
Why?
|
Fractals | 1 | 2006 | 42 | 0.020 |
Why?
|
Vision, Binocular | 1 | 2006 | 21 | 0.020 |
Why?
|
Chemistry, Clinical | 1 | 1986 | 2 | 0.020 |
Why?
|
Metabolic Clearance Rate | 4 | 1988 | 120 | 0.020 |
Why?
|
Physical Exertion | 1 | 1986 | 38 | 0.020 |
Why?
|
Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.020 |
Why?
|
Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 2397 | 0.020 |
Why?
|
Rest | 1 | 1986 | 49 | 0.020 |
Why?
|
Cricetinae | 2 | 2002 | 558 | 0.020 |
Why?
|
Hip Joint | 1 | 2006 | 54 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 125 | 0.020 |
Why?
|
Base Sequence | 1 | 2010 | 2326 | 0.020 |
Why?
|
Hyperbilirubinemia | 1 | 2005 | 21 | 0.020 |
Why?
|
Saxitoxin | 1 | 1985 | 8 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2006 | 86 | 0.020 |
Why?
|
Cardiac Output | 1 | 1986 | 156 | 0.020 |
Why?
|
Gene Library | 1 | 2006 | 133 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1986 | 112 | 0.020 |
Why?
|
International Cooperation | 1 | 1986 | 125 | 0.020 |
Why?
|
Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.020 |
Why?
|
GATA6 Transcription Factor | 1 | 2005 | 13 | 0.020 |
Why?
|
Treatment Failure | 1 | 2006 | 286 | 0.020 |
Why?
|
Half-Life | 1 | 2005 | 96 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2006 | 151 | 0.020 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 1985 | 2 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2006 | 392 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 2006 | 154 | 0.020 |
Why?
|
Azores | 1 | 2004 | 3 | 0.020 |
Why?
|
Freeze Fracturing | 4 | 1985 | 12 | 0.020 |
Why?
|
Genes, erbA | 1 | 2004 | 10 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2004 | 58 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 44 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 340 | 0.020 |
Why?
|
Biological Availability | 1 | 2004 | 92 | 0.020 |
Why?
|
Fetal Death | 2 | 1994 | 56 | 0.020 |
Why?
|
Platinum | 1 | 2004 | 63 | 0.020 |
Why?
|
Oncogenes | 1 | 2004 | 92 | 0.010 |
Why?
|
Multigene Family | 1 | 2005 | 203 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2004 | 39 | 0.010 |
Why?
|
Surveys and Questionnaires | 2 | 2003 | 2599 | 0.010 |
Why?
|
Dual Specificity Phosphatase 1 | 1 | 2004 | 17 | 0.010 |
Why?
|
Sodium | 1 | 1985 | 330 | 0.010 |
Why?
|
Protein Phosphatase 1 | 1 | 2004 | 34 | 0.010 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2004 | 46 | 0.010 |
Why?
|
Socioeconomic Factors | 2 | 1999 | 581 | 0.010 |
Why?
|
DNA | 1 | 2010 | 1307 | 0.010 |
Why?
|
Ion Channels | 1 | 1985 | 246 | 0.010 |
Why?
|
Fibroblast Growth Factors | 1 | 2004 | 79 | 0.010 |
Why?
|
Defecation | 1 | 2003 | 23 | 0.010 |
Why?
|
Surgical Stapling | 1 | 2003 | 17 | 0.010 |
Why?
|
Stroke Volume | 1 | 1986 | 460 | 0.010 |
Why?
|
Locomotion | 1 | 1984 | 138 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2004 | 524 | 0.010 |
Why?
|
Intercellular Junctions | 1 | 1983 | 68 | 0.010 |
Why?
|
Immediate-Early Proteins | 1 | 2004 | 165 | 0.010 |
Why?
|
DNA Damage | 1 | 2004 | 371 | 0.010 |
Why?
|
Computational Biology | 1 | 2006 | 542 | 0.010 |
Why?
|
Hemodynamics | 1 | 1986 | 727 | 0.010 |
Why?
|
Pedigree | 1 | 2004 | 969 | 0.010 |
Why?
|
CHO Cells | 1 | 2002 | 187 | 0.010 |
Why?
|
Leukocyte Count | 2 | 1999 | 223 | 0.010 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1982 | 103 | 0.010 |
Why?
|
Glucuronides | 1 | 2002 | 34 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2003 | 237 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2002 | 118 | 0.010 |
Why?
|
HLA-G Antigens | 1 | 2001 | 52 | 0.010 |
Why?
|
RNA | 1 | 2006 | 578 | 0.010 |
Why?
|
Uterine Rupture | 1 | 2001 | 7 | 0.010 |
Why?
|
Trial of Labor | 1 | 2001 | 5 | 0.010 |
Why?
|
Physicians | 1 | 2009 | 688 | 0.010 |
Why?
|
Cognition | 1 | 2006 | 578 | 0.010 |
Why?
|
Hospitals, Urban | 1 | 2001 | 55 | 0.010 |
Why?
|
Carcinoma, Bronchogenic | 1 | 1981 | 30 | 0.010 |
Why?
|
Immunologic Techniques | 1 | 1981 | 26 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 695 | 0.010 |
Why?
|
Obstetric Labor Complications | 1 | 2001 | 34 | 0.010 |
Why?
|
Down-Regulation | 1 | 2002 | 519 | 0.010 |
Why?
|
Poverty Areas | 1 | 2001 | 37 | 0.010 |
Why?
|
Sleep, REM | 1 | 2000 | 51 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2006 | 1697 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1982 | 575 | 0.010 |
Why?
|
Medical Records | 1 | 1981 | 120 | 0.010 |
Why?
|
Growth Hormone | 1 | 2000 | 96 | 0.010 |
Why?
|
Tablets, Enteric-Coated | 1 | 2000 | 6 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1986 | 559 | 0.010 |
Why?
|
Chickens | 3 | 1985 | 212 | 0.010 |
Why?
|
Diabetic Foot | 1 | 2000 | 14 | 0.010 |
Why?
|
Polysomnography | 1 | 2000 | 150 | 0.010 |
Why?
|
Placenta Accreta | 1 | 2000 | 7 | 0.010 |
Why?
|
Hyperglycemia | 2 | 1994 | 171 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2006 | 1233 | 0.010 |
Why?
|
Pregnancy Complications, Parasitic | 1 | 2000 | 16 | 0.010 |
Why?
|
Phlebitis | 1 | 1999 | 1 | 0.010 |
Why?
|
Sterilization, Reproductive | 1 | 2000 | 12 | 0.010 |
Why?
|
Lactulose | 1 | 2000 | 22 | 0.010 |
Why?
|
Midwestern United States | 1 | 2000 | 82 | 0.010 |
Why?
|
Cell Transformation, Viral | 2 | 1990 | 40 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 1999 | 46 | 0.010 |
Why?
|
Peptic Ulcer | 1 | 1999 | 18 | 0.010 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2000 | 46 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2000 | 46 | 0.010 |
Why?
|
Rats, Inbred Strains | 3 | 1985 | 312 | 0.010 |
Why?
|
Respiratory Tract Diseases | 1 | 1999 | 45 | 0.010 |
Why?
|
Lymphocyte Transfusion | 1 | 1999 | 41 | 0.010 |
Why?
|
Emergency Treatment | 1 | 2000 | 43 | 0.010 |
Why?
|
Cicatrix | 1 | 2000 | 66 | 0.010 |
Why?
|
Accidental Falls | 1 | 1999 | 51 | 0.010 |
Why?
|
Eye Diseases | 1 | 2000 | 58 | 0.010 |
Why?
|
Procarbazine | 2 | 1990 | 40 | 0.010 |
Why?
|
Prenatal Diagnosis | 1 | 2000 | 110 | 0.010 |
Why?
|
Aging | 3 | 1993 | 713 | 0.010 |
Why?
|
Cardiovascular Diseases | 2 | 1999 | 703 | 0.010 |
Why?
|
Herpesvirus 4, Human | 2 | 1990 | 119 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2005 | 754 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1999 | 79 | 0.010 |
Why?
|
Diabetic Retinopathy | 1 | 2000 | 91 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2000 | 301 | 0.010 |
Why?
|
Abatacept | 1 | 1998 | 85 | 0.010 |
Why?
|
Reoperation | 1 | 2001 | 598 | 0.010 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 1998 | 12 | 0.010 |
Why?
|
Diabetes Complications | 1 | 1999 | 170 | 0.010 |
Why?
|
Homeostasis | 1 | 2000 | 412 | 0.010 |
Why?
|
Radius | 1 | 1998 | 31 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2000 | 188 | 0.010 |
Why?
|
CTLA-4 Antigen | 1 | 1998 | 138 | 0.010 |
Why?
|
Gastrointestinal Agents | 1 | 2000 | 169 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2000 | 228 | 0.010 |
Why?
|
Puberty | 1 | 1998 | 60 | 0.010 |
Why?
|
Nephrosis, Lipoid | 1 | 1997 | 6 | 0.010 |
Why?
|
Mental Health | 1 | 1999 | 175 | 0.010 |
Why?
|
Nutritional Status | 1 | 1998 | 80 | 0.010 |
Why?
|
Cold Temperature | 1 | 1998 | 160 | 0.010 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 1997 | 35 | 0.010 |
Why?
|
Hormones | 1 | 1998 | 139 | 0.010 |
Why?
|
Calcium | 2 | 1998 | 1170 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 2012 | 0.010 |
Why?
|
Antigens, Plant | 1 | 1997 | 14 | 0.010 |
Why?
|
Floors and Floorcoverings | 1 | 1997 | 7 | 0.010 |
Why?
|
Age Distribution | 1 | 1997 | 201 | 0.010 |
Why?
|
Lubrication | 1 | 1997 | 2 | 0.010 |
Why?
|
Cystoscopes | 1 | 1997 | 2 | 0.010 |
Why?
|
Dosage Forms | 1 | 1997 | 7 | 0.010 |
Why?
|
Genetic Variation | 1 | 2004 | 1371 | 0.010 |
Why?
|
Hospital Charges | 1 | 1997 | 29 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 1997 | 359 | 0.010 |
Why?
|
Antigens, CD | 1 | 1998 | 466 | 0.010 |
Why?
|
Diet | 1 | 2000 | 441 | 0.010 |
Why?
|
Physicians, Family | 1 | 1997 | 39 | 0.010 |
Why?
|
Infusions, Parenteral | 2 | 1986 | 51 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1999 | 1066 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 1997 | 103 | 0.010 |
Why?
|
Health Care Surveys | 1 | 1997 | 281 | 0.010 |
Why?
|
Bacteria | 1 | 1999 | 471 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2000 | 1589 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1997 | 187 | 0.010 |
Why?
|
Illinois | 1 | 1997 | 469 | 0.010 |
Why?
|
Sheep | 2 | 1985 | 250 | 0.010 |
Why?
|
Residence Characteristics | 1 | 1997 | 198 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 1995 | 227 | 0.010 |
Why?
|
Rana pipiens | 2 | 1985 | 11 | 0.010 |
Why?
|
Amylases | 1 | 1994 | 14 | 0.010 |
Why?
|
Kinetics | 2 | 1988 | 1527 | 0.010 |
Why?
|
Cadaver | 1 | 1994 | 185 | 0.010 |
Why?
|
Cell Separation | 1 | 1994 | 198 | 0.010 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1994 | 56 | 0.010 |
Why?
|
Homozygote | 1 | 1994 | 204 | 0.010 |
Why?
|
Mice, SCID | 1 | 1994 | 261 | 0.010 |
Why?
|
Marriage | 1 | 1993 | 25 | 0.010 |
Why?
|
Rabbits | 2 | 1985 | 637 | 0.010 |
Why?
|
Rats | 3 | 1985 | 4039 | 0.010 |
Why?
|
Nucleotides | 1 | 1993 | 97 | 0.010 |
Why?
|
Fertility | 1 | 1993 | 116 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1992 | 155 | 0.010 |
Why?
|
Autoantigens | 1 | 1993 | 129 | 0.010 |
Why?
|
Glaucoma | 1 | 1992 | 33 | 0.010 |
Why?
|
Islets of Langerhans Transplantation | 1 | 1994 | 241 | 0.010 |
Why?
|
Liver | 2 | 1988 | 1204 | 0.010 |
Why?
|
Agent Orange | 1 | 1990 | 1 | 0.010 |
Why?
|
2,4,5-Trichlorophenoxyacetic Acid | 1 | 1990 | 1 | 0.010 |
Why?
|
2,4-Dichlorophenoxyacetic Acid | 1 | 1990 | 2 | 0.010 |
Why?
|
Polychlorinated Dibenzodioxins | 1 | 1990 | 3 | 0.010 |
Why?
|
Vietnam | 1 | 1990 | 14 | 0.010 |
Why?
|
Aerospace Medicine | 1 | 1990 | 17 | 0.010 |
Why?
|
Physical Examination | 1 | 1990 | 148 | 0.010 |
Why?
|
Mitomycins | 1 | 1989 | 13 | 0.010 |
Why?
|
Methylnitronitrosoguanidine | 1 | 1989 | 16 | 0.010 |
Why?
|
Mitomycin | 1 | 1989 | 29 | 0.010 |
Why?
|
Skin Diseases | 1 | 1990 | 173 | 0.010 |
Why?
|
Heart Ventricles | 2 | 1985 | 779 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1988 | 11 | 0.010 |
Why?
|
Liver Diseases | 1 | 1990 | 242 | 0.000 |
Why?
|
Vinblastine | 1 | 1988 | 108 | 0.000 |
Why?
|
Radiation Genetics | 1 | 1988 | 7 | 0.000 |
Why?
|
Cobalt Radioisotopes | 1 | 1988 | 19 | 0.000 |
Why?
|
Bleomycin | 1 | 1988 | 102 | 0.000 |
Why?
|
Neutrons | 1 | 1988 | 57 | 0.000 |
Why?
|
Gamma Rays | 1 | 1988 | 73 | 0.000 |
Why?
|
Environmental Exposure | 1 | 1990 | 321 | 0.000 |
Why?
|
Dacarbazine | 1 | 1988 | 102 | 0.000 |
Why?
|
Histocytochemistry | 1 | 1987 | 130 | 0.000 |
Why?
|
Membrane Proteins | 1 | 1994 | 1214 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1987 | 306 | 0.000 |
Why?
|
X-Rays | 1 | 1986 | 132 | 0.000 |
Why?
|
Femoral Artery | 1 | 1986 | 83 | 0.000 |
Why?
|
Mathematics | 1 | 1986 | 191 | 0.000 |
Why?
|
Amphibian Proteins | 1 | 1985 | 4 | 0.000 |
Why?
|
Xenopus | 1 | 1986 | 126 | 0.000 |
Why?
|
Sarcolemma | 1 | 1985 | 31 | 0.000 |
Why?
|
Tetrodotoxin | 1 | 1985 | 50 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1986 | 234 | 0.000 |
Why?
|
Chick Embryo | 1 | 1985 | 230 | 0.000 |
Why?
|
Radiation Tolerance | 1 | 1986 | 173 | 0.000 |
Why?
|
Purkinje Fibers | 1 | 1985 | 27 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 1990 | 737 | 0.000 |
Why?
|
Braces | 1 | 1984 | 13 | 0.000 |
Why?
|
Embryo, Nonmammalian | 1 | 1986 | 196 | 0.000 |
Why?
|
Prednisolone | 1 | 1984 | 40 | 0.000 |
Why?
|
Tendons | 1 | 1984 | 44 | 0.000 |
Why?
|
Diethylstilbestrol | 1 | 1984 | 119 | 0.000 |
Why?
|
In Vitro Techniques | 1 | 1985 | 995 | 0.000 |
Why?
|
Ventricular Function | 1 | 1983 | 53 | 0.000 |
Why?
|
Heart Atria | 1 | 1985 | 281 | 0.000 |
Why?
|
Binding Sites | 1 | 1985 | 1113 | 0.000 |
Why?
|
Axilla | 1 | 1982 | 104 | 0.000 |
Why?
|
Species Specificity | 1 | 1983 | 684 | 0.000 |
Why?
|
Myocardial Contraction | 1 | 1983 | 252 | 0.000 |
Why?
|
Action Potentials | 1 | 1985 | 595 | 0.000 |
Why?
|
Muscle Contraction | 1 | 1982 | 284 | 0.000 |
Why?
|